What is Idiopathic Short Stature?
Idiopathic short stature (ISS) is a clinical term used when a child is significantly shorter than their peers — typically below approximately the 3rd percentile, or more than 2 standard deviations below the mean height for their age and sex — and no underlying medical explanation can be found. The word "idiopathic" simply means the cause is unknown.
To receive an ISS designation, a child must generally meet all of the following criteria:
- Height more than 2 standard deviations below the mean for age and sex
- Normal growth hormone levels on standard testing
- No chronic illness, nutritional deficiency, or systemic disease
- Appropriate birth weight and length (ruling out intrauterine growth restriction)
- No identifiable chromosomal or skeletal abnormality
ISS is more common than many families realize. It is estimated to affect approximately 1 in 40 children, and it can occur in both boys and girls. In some cases, a family pattern of shorter stature is evident — one or both parents may also be shorter than average — though this alone does not fully explain why some children fall significantly below the normal range.
How ISS Differs from Growth Hormone Deficiency
ISS and growth hormone deficiency (GHD) are sometimes confused because both conditions present with short stature. However, they are distinct diagnoses with different underlying mechanisms. Understanding the difference is important for families considering evaluation.
| Idiopathic Short Stature (ISS) | Growth Hormone Deficiency (GHD) | |
|---|---|---|
| GH Levels | Normal on standard testing | Insufficient GH production confirmed by stimulation testing |
| Identified Cause | No identifiable underlying cause | Pituitary gland dysfunction (congenital, acquired, or idiopathic GHD) |
| Other Symptoms | Child is otherwise healthy | May include delayed bone age, low IGF-1, central adiposity |
| Height Profile | Significantly below average; growth rate may be slow but consistent | Often shows clear deceleration from a previous growth trajectory |
| Bone Age | May be normal or slightly delayed | Typically delayed, sometimes significantly so |
| FDA-Approved Treatment | Yes — approved in 2003 for qualifying children | Yes — approved since 1985 |
A physician evaluation is the only reliable way to distinguish between ISS, GHD, and other conditions that may affect growth. Learn more about GHD here.
Signs That May Indicate ISS
Because ISS is defined largely by what it is not — no underlying cause — the signs tend to center on persistent short stature in an otherwise healthy child. Physicians and families may notice:
Consistent Short Stature
Height has been persistently below the 3rd percentile across multiple measurements over time — not a sudden drop, but a stable pattern of being significantly shorter than peers.
Normal Health Otherwise
The child is generally healthy — no chronic illness, normal GH levels, appropriate nutrition, and normal developmental milestones in other areas. Short stature is the primary concern.
Family History of Short Stature
One or both parents, or other close relatives, may also be shorter than average. A family pattern does not rule out evaluation, particularly when the child's height is significantly below the expected range.
How is ISS Diagnosed?
ISS is a diagnosis of exclusion — meaning a physician must first rule out all identifiable causes of short stature before applying the ISS label. This requires thorough evaluation and is not a conclusion that can be reached without proper medical assessment.
Physicians typically work through the following differential diagnoses before confirming ISS:
Growth Hormone Deficiency — ruled out via IGF-1, IGFBP-3, and GH stimulation testing
Thyroid Disorders — hypothyroidism can impair growth; ruled out via thyroid function tests
Celiac Disease — malabsorption from undiagnosed celiac can cause growth faltering; detected via antibody testing
Chromosomal Abnormalities — Turner syndrome (in girls) and other chromosomal conditions can affect height; identified via karyotype testing when appropriate
Skeletal Dysplasias — bone and cartilage disorders that affect growth; evaluated through physical examination and bone X-rays
Chronic Illness — conditions affecting the kidneys, heart, gastrointestinal tract, or other organ systems; assessed through clinical history and blood work
When all of the above have been appropriately excluded, testing that is typically part of the ISS workup includes:
Comprehensive Blood Panel
A broad blood workup to assess general health, organ function, thyroid levels, and markers that may indicate systemic disease or nutritional deficiency.
IGF-1 and IGFBP-3 Levels
These blood markers reflect overall growth hormone activity. In ISS, IGF-1 levels are typically within the normal range — distinguishing ISS from GHD.
Bone Age X-ray
An X-ray of the left hand and wrist to determine skeletal maturity. Bone age in ISS may be normal or slightly delayed, which also helps estimate remaining growth potential.
Growth Chart Analysis
Detailed review of the child's growth history — including height velocity over time — to characterize the pattern of short stature and compare to family height targets.
FDA Approval for ISS Treatment
✅ A Recognized and Evaluated Treatment Pathway
In 2003, the U.S. Food and Drug Administration (FDA) approved recombinant human growth hormone (somatropin) therapy for children with idiopathic short stature, making ISS one of the approved indications for pediatric growth hormone treatment in the United States.
FDA Approval Criteria for ISS Treatment Include:
- Height more than 2.25 standard deviations below the mean for age and sex
- Child is unlikely to achieve a normal adult height without intervention
- Open growth plates confirmed on bone age X-ray (treatment window still available)
It is important to understand that FDA approval does not mean every child with ISS is a candidate for treatment. Whether a specific child is an appropriate candidate is a medical decision that requires comprehensive physician evaluation, consideration of the child's full growth history, bone age, predicted adult height, and the family's informed understanding of what clinical studies suggest about potential outcomes.
The Role of Timing
⏳ Growth Plates and the Treatment Window
Growth hormone therapy — whether for GHD or ISS — is only possible while a child's growth plates (epiphyseal plates) remain open and unfused. Once growth plates close, typically during mid-to-late adolescence, linear height growth is no longer possible regardless of treatment.
This means that the window for physician-guided evaluation and consideration of treatment is time-limited. Earlier evaluation allows more time for thorough diagnostic workup, informed family decision-making, and — if a physician determines treatment is appropriate — a longer potential duration of therapy while growth potential remains.
If you have concerns about your child's growth, speaking with a specialist sooner rather than later helps preserve options. Reaching out does not commit your family to any particular course of action — it simply opens a conversation with a qualified physician.
Emotional and Social Impact of Short Stature
Acknowledging What Families Experience
Short stature — regardless of its cause — can carry real psychosocial weight for children and their families. Children who are significantly shorter than their peers may experience teasing or exclusion, and some report challenges with self-esteem, social confidence, and emotional well-being during childhood and adolescence.
These experiences are valid and deserve to be taken seriously. While clinical studies suggest that physician-supervised growth evaluation and treatment (when appropriate) may have both physical and psychosocial benefits for some patients, outcomes vary and no specific result can be promised. What we can say is that understanding your child's options — and having an open, informed conversation with a qualified physician — is a meaningful step that many families find valuable in itself.
HGHKids.com is here to help families access that conversation. Our role is to connect you with licensed specialists who can provide a proper evaluation and answer your questions in a medical context.